El trabajo colaborativo contains an investigator of the Las Escuelas de Medicina de la Universidad Central del Caribe, Escuela de Medicina San Juan Bautista en la Universidad de Puerto Rico.
Belinda Z. Burgos
Agencia Latina de Noticias Medicina y Salud Pública
The drugs against the most common cancers such as cisplatin, doxorrubicina, paclitaxel and fluorouracilo have developed resistance to cancer cells, in their distinct mechanisms of action in the variation in genetic expressions that pescafect.
For this reason, Puerto Rican investigators are looking at the travel rates in the deepest pages of the scientific literature to develop a clinical arm that will help patients, physicians, health professionals and patients to be aware of what they are doing. of treatments, the genes associated with the development of distinct cancer and above all, the importance of promoting treatment with non-toxic and more specific hash of registered tumor activity, as its drugs developed at the nanopartial base
In this scientific collaboration is one: Zally Torres Martínez, of the Department of Chemistry of the University of Puerto Rico; Wear. Yamixa Delgado, Department of Biochemistry of the San Juan Bautista School of Medicine; doctors Yancy Ferrer Acosta and Ivette Suárez Arroyo, employees of the School of Medicine of the Central University of the Caribbean (UCC), among other relevant authors in the Department of Neuroscience of the same institution.
The studio was recently published in the magazine “Weerstand teen kanker”. Cabe points out that while antibiotic resistance is increasing in a public health problem, we are assimilating the resistance of therapies to cancer and have affected the prognosis against these diseases in different patient populations, due to their genetics.
“More than 232 analyzed publications have been released that will search the breaches”, which has been located in scientific works in the age of drug resistance to cancer. Our intention is that both the doctors and the investigators, including patients, are superior in a single piece of scientific material that are the main genes that influence the development of a variety of cancers in different organs and promote their resistance to treatment. doctor Delgado interviewed with Medicina y Salud Pública (MSP).
“Part of my experience is with drug delivery vehicles, as well as the nanoparticles included in this work, these drug delivery systems can help reduce this conference conferred with the regular chemotherapy therapies we know.”
For its part, the Dra. Suárez understands that the medicine of the present is moving to combine therapies against cancer to avoid resistance or, looking for alternatives and remedies for which the measure is more specific, as for example the use of nanoparticles, scientifically pleasing figures.
“For example, cisplatin medicine is a first-line treatment for pulmonary cancer, but it is known for patient resistance to this treatment. It is hoped that even if the tumor does not grow on its own, it will not be able to do anything about it, ”he said. Ferrer.
“These offerings to the investigators can be known to all those resistance genes that are active with distinctive acts such as, for example, the cisplatino”, he said.
Hecho, the article describes how the Federal Administration of Drugs and Foods (FDA, for its seals in English) has approved drugs based on nanoparticles based on nanoparticles of organic material, polymer, liposomes (compared with slightly absorbed) , between others.
For example, the article mentions the genes CHD4, p53, MDRI, BRCA1 and BRCA2, GLIPR1, EGFR, among others, as those that mutate, can give to the development of cancerous diseases or promote resistance to treatment.
“It is possible to modify the treatments or replacements for others if it is known that a patient has some of these mutated genes and that patients do not develop resistance to therapies,” he said.
The development of new therapeutic and non-cytotoxic modalities constitutes the new modality of hacerle frente to this problem of public health.
See more here